Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017;13(3):244-250.
doi: 10.2174/1573403X13666170510115628.

Is the Hepatic Factor a miRNA that Maintains the Integrity of Pulmonary Microvasculature by Inhibiting the Vascular Endothelial Growth Factor?

Joseph J Vettukattil  1
Affiliations
Review

Is the Hepatic Factor a miRNA that Maintains the Integrity of Pulmonary Microvasculature by Inhibiting the Vascular Endothelial Growth Factor?

Joseph J Vettukattil. Curr Cardiol Rev. 2017.

Abstract

Background: The "hepatic factor," a molecule or group of molecules present in the hepatic venous blood, essential for the prevention of the development of pulmonary arteriovenous malformations (PAVMs) and right-to-left shunting has been a conceptual enigma in the understanding of many related conditions.

Methods: Patients with various forms of liver diseases including acute hepatic failure, and others with normal hepatic function like hereditary hemorrhagic telangiectasia (HHT), inflammatory and parasitic disorders, cardiogenic hepatopulmonary syndrome (cHPS) and skin disorders like Dyskeratosis congenita are all known to cause PAVMs. Over a period of the last two decades our understanding of the pathogenesis of PAVMs has changed, but the mechanisms are still not clearly understood. The presence of PAVMs once considered a contraindication for liver transplantation is now a cure for PAVMs in patients with HPS.

Results: In this article the molecular mechanisms and the underlying pathogenesis of PAVMs are discussed and the role of microRNA (miRNA) in its pathogenesis is favorably argued. Identifying and preventing or treating the underlying mechanisms will significantly influence the management of a large group of patients who at present cannot be effectively treated with a very poor prognosis. Progressive polycythemia, desaturation, stroke, and infection are serious complications of PAVMs.

Conclusion: The clinical data and current understanding leads to the possible role of miRNA, which inhibits Vascular Endothelial Growth Factor (VEGF) synthesis as a pathogenic mechanism for the development of PAVMs.

Keywords: Endoglin; hepatic factor; hepatopulmonary syndrome; hereditary hemorrhagic telangiectasia; miRNA; pulmonary arteriovenous malformations; vascular endothelial growth factor.

PubMed Disclaimer

Figures

Fig. (1)
Fig. (1)
Angiogram of a patient with SCPA showing injection of contrast into the SVC flowing directly into the pulmonary arteries.
Fig. (2)
Fig. (2)
Schematic diagram illustrating the molecular basis for the development of PAVMs.
See this image and copyright information in PMC

References

    1. Srivastava D., Preminger T., Lock J.E., et al. Hepatic venous blood and the development of pulmonary arteriovenous malformations in congenital heart disease. Circulation. 1995;92(5):1217–1222. - PubMed
    1. Stoller J.K., Hoffman R.M., White R.D., Mee R.B. Anomalous hepatic venous drainage into the left atrium: an unusual cause of hypoxemia. Respir. Care. 2003;48(1):58–62. - PubMed
    1. Shah M.J., Rychik J., Fogel M.A., Murphy J.D., Jacobs M.L. Pulmonary AV malformations after superior cavopulmonary connection: resolution after inclusion of hepatic veins in the pulmonary circulation. Ann. Thorac. Surg. 1997;63(4):960–963. - PubMed
    1. Glenn W.W. Circulatory bypass of the right side of the heart. IV. Shunt between superior vena cava and distal right pulmonary artery; report of clinical application. N. Engl. J. Med. 1958;259(3):117–120. - PubMed
    1. Vettukattil J.J., Slavik Z., Lamb R.K., et al. Intrapulmonary arteriovenous shunting may be a universal phenomenon in patients with the superior cavopulmonary anastomosis: a radionuclide study. Heart. 2000;83(4):425–428. - PMC - PubMed

MeSH terms

Substances

Supplementary concepts